drugset

drugset / Trial / NCT06239623

ERK Inhibitor JSI-1187 in Advanced Solid Tumors

NCT06239623 ↗

Phase 1 Unknown 60 enrolled JS InnoPharm, LLC

NaSingle-groupOpen-labelTreatment

Summary

JSI-1187-101 phase 1 study

Timeline

Start: 2022-04-02
Primary completion: 2024-09-28
Completion: 2024-12-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	JSI-1187	Unknown	—	—

Indications